
## Jan SchjÃ,tt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3671487/publications.pdf Version: 2024-02-01



ΙΔΝ SCHIÃ ΤΤ

#	Article	IF	CITATIONS
1	A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release, 2016, 243, 172-181.	9.9	332
2	Analysis of questions about use of drugs in breastfeeding to Norwegian drug information centres. International Breastfeeding Journal, 2018, 13, 1.	2.6	43
3	Risk perception regarding drug use in pregnancy. American Journal of Obstetrics and Gynecology, 2017, 216, 375-378.	1.3	41
4	Advice on Drug Safety in Pregnancy. Drug Safety, 2008, 31, 799-806.	3.2	33
5	Challenges adhering to a medication regimen following first-time percutaneous coronary intervention: A patient perspective. International Journal of Nursing Studies, 2018, 88, 16-24.	5.6	32
6	Drug Information Services Today: Current Role and Future Perspectives in Rational Drug Therapy. Clinical Therapeutics, 2016, 38, 414-421.	2.5	30
7	Quality and impact of problem-oriented drug information: a method to change clinical practice among physicians?. European Journal of Clinical Pharmacology, 2002, 57, 897-902.	1.9	24
8	Teratogenic Risk Perception and Confidence in Use of Medicines in Pairs of Pregnant Women and General Practitioners Based on Patient Information Leaflets. Drug Safety, 2013, 36, 481-489.	3.2	23
9	Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines. Drug Metabolism and Disposition, 2020, 48, 153-158.	3.3	23
10	A question–answer pair (QAP) database integrated with websites to answer complex questions submitted to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive study. BMJ Open, 2012, 2, e000642.	1.9	22
11	Liquid chromatography/tandem mass spectrometry method for simultaneous quantification of eight endogenous nucleotides and the intracellular gemcitabine metabolite dFdCTP in human peripheral blood mononuclear cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1001, 212-220.	2.3	22
12	Antipsychotic Drugs and Risk of Hip Fracture in People Aged 60 and Older in Norway. Journal of the American Geriatrics Society, 2016, 64, 1203-1209.	2.6	20
13	Drug use in pregnancy—physicians' evaluation of quality and clinical impact of drug information centres. European Journal of Clinical Pharmacology, 2009, 65, 303-308.	1.9	19
14	Which factors predict the time spent answering queries to a drug information centre?. International Journal of Clinical Pharmacy, 2010, 32, 799-804.	1.4	19
15	Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells. Pharmaceutics, 2020, 12, 141.	4.5	17
16	Myocardial injury in a 41-year-old male treated with methylphenidate: a case report. BMC Research Notes, 2014, 7, 480.	1.4	13
17	Benefits of a national network of drug information centres: RELIS. European Journal of Clinical Pharmacology, 2017, 73, 125-126.	1.9	12
18	A short-time model to study relevant indices of cardiotoxicity of doxorubicin in the rat. Toxicology Mechanisms and Methods, 2013, 23, 412-418.	2.7	11

Jan SchjÃ<sub>s</sub>tt

#	Article	IF	CITATIONS
19	Factors associated with time consumption when answering drug-related queries to Scandinavian drug information centres: a multi-centre study. European Journal of Clinical Pharmacology, 2014, 70, 1395-1401.	1.9	11
20	Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids. Substance Abuse and Rehabilitation, 2015, 6, 131.	4.8	10
21	Physicians' Perception of Teratogenic Risk and Confidence in Prescribing Drugs in Pregnancy—Influence of Norwegian Drug Information Centers. Clinical Therapeutics, 2016, 38, 1102-1108.	2.5	10
22	Preanalytical Stability of Gemcitabine and its Metabolite 2′, 2′-Difluoro-2′-Deoxyuridine in Whole Blood—Assessed by Liquid Chromatography Tandem Mass Spectrometry. Journal of Pharmaceutical Sciences, 2015, 104, 4427-4432.	3.3	9
23	Analysis of consensus among drug interaction databases with regard to combinations of psychotropics. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 126-132.	2.5	9
24	Hepatitis Caused by Lotusâ€f3?. Basic and Clinical Pharmacology and Toxicology, 2009, 104, 414-416.	2.5	8
25	Relationship Between Time Consumption and Quality of Responses to Drug-related Queries: A Study From Seven Drug Information Centers in Scandinavia. Clinical Therapeutics, 2016, 38, 1738-1749.	2.5	8
26	Ciprofloxacin and acute aortic valve damage. Medical Hypotheses, 2018, 121, 35.	1.5	7
27	Joint medicine-information and pharmacovigilance services could improve detection and communication about drug-safety problems. Drug, Healthcare and Patient Safety, 2014, 6, 89.	2.5	6
28	Quality assessment of structure and language elements of written responses given by seven Scandinavian drug information centres. European Journal of Clinical Pharmacology, 2017, 73, 623-631.	1.9	6
29	A retrospective comparison of inappropriate prescribing of psychotropics in three Norwegian nursing homes in 2000 and 2016 with prescribing quality indicators. BMC Medical Informatics and Decision Making, 2019, 19, 102.	3.0	6
30	SafeMotherMedicine: Aiming to Increase Women's Empowerment in Use of Medications During Pregnancy and Breastfeeding. Maternal and Child Health Journal, 2020, 24, 531-536.	1.5	6
31	Questions about complementary and alternative medicine to the Regional Medicines Information and Pharmacovigilance Centres in Norway (RELIS): a descriptive pilot study. BMC Complementary and Alternative Medicine, 2014, 14, 56.	3.7	5
32	Physicians' questions concerning drug use among older patients: experience from Norwegian drug information centres (RELIS) in the period 2010–2015. Aging Clinical and Experimental Research, 2018, 30, 867-870.	2.9	5
33	Drug information centres and their provision of decision support: The Scandinavian experience. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 489-492.	1.5	4
34	Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome. Clinical Therapeutics, 2019, 41, 806-814.	2.5	3
35	Quetiapine, Misuse and Dependency: A Case-Series of Questions to a Norwegian Network of Drug Information Centers. Drug, Healthcare and Patient Safety, 2021, Volume 13, 151-157.	2.5	3
36	Ultrasound and Microbubbles Enhance Uptake of Doxorubicin in Murine Kidneys. Pharmaceutics, 2021, 13, 2038.	4.5	3

Jan SchjÃ,tt

#	Article	IF	CITATIONS
37	Use of References in Responses from Scandinavian Drug Information Centres. Medicines (Basel,) Tj ETQq1 1 0.	784314 rgB1 1.4	[ /Overlock
38	Disproportionality analysis for identification of drug safety signals in a database shared by the Norwegian network of drug information centres (RELIS). European Journal of Clinical Pharmacology, 2019, 75, 1469-1470.	1.9	2
39	The Possibility of Therapeutic Drug Monitoring of the Most Important Interactions in Nursing Homes. Current Clinical Pharmacology, 2019, 14, 152-156.	0.6	2
40	Stability of Antidepressants and Antipsychotics in Gel Separator Tubes. Therapeutic Drug Monitoring, 2019, 41, 249-250.	2.0	2
41	Review of Questions Concerning Clinical Drug Interactions in ADHD Treatment From Physicians in Norway. Frontiers in Pharmacology, 2020, 11, 607915.	3.5	2
42	Ultrasound and microbubble assisted drug delivery – A clinical pharmacological perspective. Pharmacological Research, 2021, 165, 105475.	7.1	2
43	The possibility of hypersensitivity myocarditis following COVID-19 vaccines: Implications for contrast echocardiography. Cardiology, 0, , .	1.4	2
44	Norwegian drug information centres strongly promote person-centred and personalised medicine: a brief report on the achievements and strategy. EPMA Journal, 2019, 10, 109-114.	6.1	1
45	Review of Clinical Questions Submitted to Norwegian Drug Information Centres Concerning Administration and Dosage to Older Patients of Relevance to Patient-Centric Care. Pharmaceutics, 2021, 13, 105.	4.5	1
46	Acute Myocardial Injury in a Patient with Attention Deficit Hyperactivity Disorder and History of Substance Abuse: A Multimodality Imaging Point of View. Journal of Cardiovascular Development and Disease, 2021, 8, 67.	1.6	1
47	Pretreatment with Tamoxifen does not Change Acute Epirubicin Cardiotoxicity in Rats. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 231-234.	2.5	0
48	Shortage of Digitoxin and Switching to Digoxin in Norway: A Retrospective Study of Blood Samples Submitted to a Clinical Pharmacology Laboratory. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 74-77.	2.5	0
49	Distribution of Psychotropic Drugs Into Lipoproteins. Therapeutic Drug Monitoring, 2019, 41, 766-771.	2.0	0
50	Perception of prescribing factors and purchase statistics of non-steroidal anti-inflammatory drugs in an orthopedic clinic. BMC Research Notes, 2020, 13, 100.	1.4	0
51	Second Opinion in Pharmacotherapy of ADHD: Do Not Postpone It!. Clinical Therapeutics, 2022, , .	2.5	0